Paper42657161
Oral selective estrogen receptor degraders and biomarker-driven therapy in ER-positive breast cancer: mechanisms, clinical evidence, and future directions.
Alasheev AY and 3 others. Front Oncol, 2026. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. Oral selective estrogen receptor degraders and biomarker-driven therapy in ER-positive breast cancer: mechanisms, clinical evidence, and future directions. Papers, record 42657161. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42657161
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Oral selective estrogen receptor degraders and biomarker-driven therapy in ER-positive breast cancer: mechanisms, clinical evidence, and future directions.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
Comments and corrections1
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers |
|---|---|---|---|
| Erratum in | 42889272 | Correction: Oral selective estrogen receptor degraders and biomarker-driven therapy in ER-positive breast cancer: mechanisms, clinical evidence, and future directions. | https://conductscience.org/library/papers/42889272 |
Source PubMed
References41
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 37657462 | Neoadjuvant palbociclib plus either giredestrant or anastrozole in oestrogen receptor-positive, HER2-negative, early breast cancer (coopERA Breast Cancer): an open-label, randomised, controlled, phase 2 study. | Lancet Oncol | 2023 | https://conductscience.org/library/papers/37657462 | PubMed |
| 2 | 38572751 | Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. | CA Cancer J Clin | 2024 | https://conductscience.org/library/papers/38572751 | PubMed |
| 3 | 38819400 | Oral Estrogen Receptor PROTAC Vepdegestrant (ARV-471) Is Highly Efficacious as Monotherapy and in Combination with CDK4/6 or PI3K/mTOR Pathway Inhibitors in Preclinical ER+ Breast Cancer Models. | Clin Cancer Res | 2024 | https://conductscience.org/library/papers/38819400 | PubMed |
| 4 | 40702893 | NDA Submission of Vepdegestrant (ARV-471) to U.S. FDA: The Beginning of a New Era of PROTAC Degraders. | J Med Chem | 2025 | https://conductscience.org/library/papers/40702893 | PubMed |
| 5 | 35642432 | Covalent ERα Antagonist H3B-6545 Demonstrates Encouraging Preclinical Activity in Therapy-Resistant Breast Cancer. | Mol Cancer Ther | 2022 | https://conductscience.org/library/papers/35642432 | PubMed |
| 6 | 37377342 | Targeting the Estrogen Receptor for the Treatment of Breast Cancer: Recent Advances and Challenges. | J Med Chem | 2023 | https://conductscience.org/library/papers/37377342 | PubMed |
| 7 | 38811701 | Innovative cancer therapies offer new hope. | Nature | 2024 | https://conductscience.org/library/papers/38811701 | PubMed |
| 8 | 20855825 | Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. | J Clin Oncol | 2010 | https://conductscience.org/library/papers/20855825 | PubMed |
| 9 | 37348019 | AMEERA-3: Randomized Phase II Study of Amcenestrant (Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Monotherapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer. | J Clin Oncol | 2023 | https://conductscience.org/library/papers/37348019 | PubMed |
| 10 | 36224343 | Molecular targeted therapy for anticancer treatment. | Exp Mol Med | 2022 | https://conductscience.org/library/papers/36224343 | PubMed |
| 11 | 20824023 | Endocrine Therapy - What Else? | Breast Care (Basel) | 2008 | https://conductscience.org/library/papers/20824023 | PubMed |
| 12 | 31630379 | Advances in Endocrine-Based Therapies for Estrogen Receptor-Positive Metastatic Breast Cancer. | Drugs | 2019 | https://conductscience.org/library/papers/31630379 | PubMed |
| 13 | 39660834 | Imlunestrant with or without Abemaciclib in Advanced Breast Cancer. | N Engl J Med | 2025 | https://conductscience.org/library/papers/39660834 | PubMed |
| 14 | 37258523 | Estrogen/HER2 receptor crosstalk in breast cancer: combination therapies to improve outcomes for patients with hormone receptor-positive/HER2-positive breast cancer. | NPJ Breast Cancer | 2023 | https://conductscience.org/library/papers/37258523 | PubMed |
| 15 | 4167125 | The results of adrenalectomy in advanced breast cancer in 500 consecutive patients. | Surg Gynecol Obstet | 1967 | https://conductscience.org/library/papers/4167125 | PubMed |
| 16 | 27908454 | Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial. | Lancet | 2016 | https://conductscience.org/library/papers/27908454 | PubMed |
| 17 | 34028522 | The physiological role of estrogen receptor functional domains. | Essays Biochem | 2021 | https://conductscience.org/library/papers/34028522 | PubMed |
| 18 | 9747868 | Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. | J Natl Cancer Inst | 1998 | https://conductscience.org/library/papers/9747868 | PubMed |
| 19 | 20404000 | Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer. | Cancer Prev Res (Phila) | 2010 | https://conductscience.org/library/papers/20404000 | PubMed |
| 20 | 15894097 | Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. | Lancet | 2005 | https://conductscience.org/library/papers/15894097 | PubMed |
Cited by1
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 0 citations.
| PMID | Title | Journal | Year | In Papers |
|---|---|---|---|---|
| 42970051 | Camizestrant (Etcamah®): an oral estrogen receptor degrader and estrogen receptor antagonist approved for breast cancer. | Med Chem Res | 2026 | https://conductscience.org/library/papers/42970051 |
Source PubMed
Genes3
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| EREG | 2069 | PubTator's text mining | https://conductscience.org/library/genes/2069 | NCBI Gene |
| ESR1 | 2099 | PubTator's text mining | https://conductscience.org/library/genes/2099 | NCBI Gene |
| PIK3CB | 5291 | PubTator's text mining | https://conductscience.org/library/genes/5291 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42657161
GET https://conductscience.org/api/papers/v1/42657161/references?page=2